Avicanna Inc. (AVCNF)
OTCMKTS
· Delayed Price · Currency is USD
0.203
0.00 (0.00%)
Dec 24, 2024, 3:00 PM EST
Avicanna Revenue
Avicanna had revenue of 6.27M CAD in the quarter ending September 30, 2024, with 0.34% growth. This brings the company's revenue in the last twelve months to 24.90M, up 109.66% year-over-year. In the year 2023, Avicanna had annual revenue of 16.79M with 314.82% growth.
Revenue (ttm)
24.90M CAD
Revenue Growth
+109.66%
P/S Ratio
n/a
Revenue / Employee
286.16K CAD
Employees
87
Market Cap
24.51M USD
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Avicanna News
- 24 days ago - Avicanna Completes First Delivery of Proprietary Topical Products to Multinational Pharmaceutical Company - GlobeNewsWire
- 5 weeks ago - Avicanna Reports Q3 2024 - GlobeNewsWire
- 7 weeks ago - Avicanna Announces Closing of Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca - GlobeNewsWire
- 4 months ago - Avicanna Announces Repayment of Debentures - GlobeNewsWire
- 4 months ago - Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology - GlobeNewsWire
- 4 months ago - Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark - GlobeNewsWire
- 4 months ago - Avicanna Reports Q2 2024 - GlobeNewsWire